financetom
Business
financetom
/
Business
/
Nextracker Shares Rise After Reporting Higher Fiscal Q2 Results; Fiscal 2025 Earnings Guidance Raised
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nextracker Shares Rise After Reporting Higher Fiscal Q2 Results; Fiscal 2025 Earnings Guidance Raised
Nov 3, 2024 3:54 PM

12:39 PM EDT, 10/31/2024 (MT Newswires) -- Nextracker ( NXT ) shares were up over 24% in recent Thursday trading after the company posted late Wednesday higher fiscal Q2 results and raised its fiscal 2025 earnings guidance.

The company reported fiscal Q2 adjusted earnings of $0.97 per diluted share, up from $0.65 a year earlier.

Analysts polled by Capital IQ expected $0.61 a share.

Revenue for the quarter ended Sept. 27 was $635.6 million, up from $573.4 million a year earlier.

Analysts surveyed by Capital IQ expected $613.5 million.

The company said it now expects fiscal 2025 adjusted EPS to range between $3.10 and $3.30, compared with a prior view of $2.89 to $3.09.

Analysts polled by Capital IQ expect $3.17 a share.

The company said it continues to expect fiscal 2025 revenue in the range of $2.8 billion to $2.9 billion.

Analysts polled by Capital IQ expect $2.86 billion.

Price: 39.86, Change: +7.89, Percent Change: +24.68

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
American Axle & Manufacturing Q3 Adjusted Earnings Fall, Net Sales Rise; Updates 2025 Sales Guidance
American Axle & Manufacturing Q3 Adjusted Earnings Fall, Net Sales Rise; Updates 2025 Sales Guidance
Nov 7, 2025
08:22 AM EST, 11/07/2025 (MT Newswires) -- American Axle & Manufacturing ( AXL ) reported Q3 adjusted earnings Friday of $0.16 per share, down from $0.20 a year earlier. Analysts polled by FactSet expected $0.12. Net sales for the quarter ended Sept. 30 were $1.51 billion, compared with $1.50 billion a year earlier. Analysts surveyed by FactSet expected $1.53 billion....
Market Chatter: Eli Lilly's Mounjaro Overtakes GSK's Augmentin as India's Top-Selling Drug in October
Market Chatter: Eli Lilly's Mounjaro Overtakes GSK's Augmentin as India's Top-Selling Drug in October
Nov 7, 2025
08:22 AM EST, 11/07/2025 (MT Newswires) -- Eli Lilly's ( LLY ) injectable diabetes treatment Mounjaro has become the top-selling drug in India, surpassing GSK's (GSK) antibiotic Augmentin, Reuters reported Friday, citing data from research firm Pharmarack. Mounjaro, also used as a weight-loss therapy, registered sales of 1 billion rupees ($11.3 million) in October against Augmentin sales of 800 million...
Form 8.3
Form 8.3
Nov 7, 2025
LONDON--(BUSINESS WIRE)--   Ap27 FORM 8.3 IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION (a) Full name of discloser Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed,...
Novo Nordisk expects negative low single-digit impact on global sales growth in 2026 (Nov 6)
Novo Nordisk expects negative low single-digit impact on global sales growth in 2026 (Nov 6)
Nov 7, 2025
Nov 6 (Reuters) - Novo Nordisk said it currently expects an estimated negative low single-digit impact to global sales growth in 2026 after the drugmaker unveiled a deal on Thursday to slash prices of popular GLP-1 weight-loss drugs for U.S. government-backed insurance programs and cash payers. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved